Basic Information
AKEAGEN is a next-generation single-domain antibody technology platform and immuno-oncology drug developer dedicated to discovering and developing effective and highly differentiated human antibody therapies to improve the lives of patients with serious diseases. We focus our R&D efforts on immuno-oncology and autoimmune indications, an area with highly unmet needs. Our unique approach and portfolio are based on our leading proprietary Akeagen mouse platform technology, which efficiently generates innovative bispecific antibodies with superior properties for drug development. AKEAGEN is engaged in strategic collaborations with globally leading pharmaceutical companies and institutions and has multiple promising candidates in early and late preclinical development.